Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation

Cancer

Volumn 80, Issue 4, 1997, Pages 764-775

  Zagars, Gunar K ^a   Pollack, Alan ^a   Von Eschenbach, Andrew C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adjuvant treatment; Androgen ablation; Prognostic factors; Prostate carcinoma; Radiation therapy

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; HIGH RISK PATIENT; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0030802946     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970815)80:4<764::AID-CNCR16>3.0.CO;2-R     Document Type: Article

References (43)

1. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993;72:1709-25.
2. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
3. Roach III M, Meehan S, Kroll S, Weil M, Ryu J, Small EJ, et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol 1996;156:1719-23.
4. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh DC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-25.
5. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors in clinically localized prostate cancer. Analysis of 938 patients irradiated in the PSA era. Cancer 1997;79:1370-80.
6. Zagars GK, Geara FB, Pollack A, von Eschenbach AC. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy. Cancer 1994;73:1904-12.
7. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995;154: 1447-52.
8. Zagars GK, Ayala AG, von Eschenbach AC, Pollack A. The prognostic significance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 1995;31:237-45.
9. Hanks GE. The challenge of treating node-positive prostate cancer: an approach to resolving the questions. Cancer 1993;71:1014-8.
10. Myers RP, Larson-Keller JJ, Bergstrahl EJ, Zincke H, Oesterling JE, Lieber MM. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer; results of long-term followup. J Urol 1992;147:910-5.
11. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843-9.
12. Zagars GK, von Eschenbach AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation. Cancer 1993;72:538-48.
13. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42.
14. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for Stage D1 (N1 to N3, MO) prostate cancer. Prognostic variables and outcome. J Urol 1994;151: 1330-3.
15. Sands ME, Pollack A, Zagars GK. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys 1995;31:13-9.
16. Pollack A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high risk prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:13-20.
17. Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:47-53.
18. Zagars GK, Sherman NE, Babaian RJ. Prostate-specific antigen and external beam radiotherapy in prostate cancer. Cancer 1991;67:412-20.
19. McDowell GC, Johnson JW, Tenney DM, Johnson DE. Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases. Urology 1990;35:476-82.
20. Sands ME, Zagars GK, Pollack A, von Eschenbach AC. Serum prostate-specific antigen, clinical stage, pathologic grade and the incidence of nodal metastases in prostate cancer. Urology 1994;44:215-20.
21. Roy AV, Bower ME, Hayden JE. Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 1971;17:1093-102.
22. Zagars GK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 33:23-35.
23. Greskovich FJ, Zagars GK, Sherman NE, Johnson DE. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol 1991;146: 798-802.
24. Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker, 1991:5-125.
25. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis 1978;31:557-60.
26. U.S. Department of Health, Education, and Welfare. Vital Statistics of the United States, 1988. Hyattsville, Maryland: Public Health Service National Center for Health Statistics 1988.
27. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991:50-250.
28. Babaian RJ, Orlando RP. Elevated prostatic acid phosphatase: a prognostic factor for stage C adenocarcinoma of the prostate. J Urol 1986;122:176-7.
29. Partin AW, Mohler JL, Piantadosi S, Brendler CB, Sanda MG, Walsh PC, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-8.
30. Zincke H, Utz DC, Taylor WF. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostate cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 1986;135:1199-205.
31. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
32. deKernion JB, Neuwirth H, Stein A, Stenzl A, Hannah J, Blyth B. Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 1990;144:700-3.
33. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142:332-6.
34. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of conservative treatment. Scand J Urol 1980;55(Suppl):99-102.
35. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate. Long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14:1085-91.
36. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in stage B2 (T2bNxMo) prostate cancer. J Urol 1995;154:424-8.
37. van Poppel H, deRidder D, Elgamal AA, deVoorde WV, Werbrouck P, Ackaert K, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol 1995;154: 429-34.
38. Whittington R, Malkowicz SB, Barnes MM, Broderick GA, van Arsdalen K, Dougherty MJ, et al. Combined hormonal and radiation therapy for lymph node-positive prostate cancer. Urology 1995;46:213-9.
39. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R, Storme G, et al. Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the EORTC radiotherapy and genitourinary tract cancer cooperative groups [abstract]. J Clin Oncol 1996;15:591.
40. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45: 616-23.
41. Denis LJ, Whelan P, DeMoura JL, Newlings D, Bono A, De-Pauw M. Goserelin acetate and flutamide versus bilateral orchiectomy. A phase II EORTC trial (30853) Urology 1993; 42:119-30.
42. Crawford ED, Eisengerger MA, McLeod DG, Spaulding JT, Benson M, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med 1989;321:419-24.
43. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.